1. Scrip
  2. >>Conferences
  3. >>ASCO

Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

 
• By Alaric DeArment

While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.

3d illustration of T cells or cancer cells
Fate Therapeutics presented early data at ASCO on its NK cell therapy program • Source: Shutterstock

Fate Therapeutics, Inc.’s natural killer (NK) cell therapy FT516 is still early and requires longer follow-up to determine if the responses it has produced in non-Hodgkin lymphoma (NHL) patients when combined with Roche Holding AG’s Rituxan (rituximab) are durable. Still, its early data gives a positive sign about the potential of the company’s pipeline, as well as FT516’s applicability beyond NHL and other hematological cancers.

The company presented Phase I data on FT516/Rituxan in a poster at the American Society of Clinical Oncology

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 
• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.

Reflections From Biotech Leader John Maraganore

 
• By Jessica Merrill

The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.